Calliditas Therapeutics AB (publ) (CALT) Stock Price, News & Analysis

Company Overview

Calliditas Therapeutics AB (publ) is a Sweden-based biopharmaceutical company dedicated to the development and commercialization of novel therapies for rare immunologic and renal diseases. The company’s scientific focus centers on targeting the underlying causes of immune-mediated conditions with oral and biologic formulations. By leveraging proprietary drug delivery technologies, Calliditas aims to bring differentiated treatments to patients who currently have limited therapeutic options.

The company’s lead product, Tarpeyo® (budesonide) delayed-release capsules, received U.S. Food and Drug Administration (FDA) approval in October 2021 for the treatment of adults with primary immunoglobulin A (IgA) nephropathy at risk of rapid disease progression. Calliditas holds exclusive commercial rights for Tarpeyo in North America and several other territories, and it continues to pursue regulatory submissions and market access efforts in Europe and select international markets. In parallel, the company is advancing a preclinical pipeline of novel immunomodulatory compounds aimed at expanding its rare disease portfolio.

Founded in 2004 and headquartered in Stockholm, Calliditas Therapeutics maintains operations across Europe and North America, supported by a corporate office in Boston to oversee U.S. commercialization activities. The company is publicly traded on the Nasdaq Stockholm exchange as well as on the Nasdaq Global Select Market in the United States under the ticker symbol CALT. Calliditas is led by an experienced management team with backgrounds in biopharmaceutical research, regulatory affairs and commercial strategy, positioning the company to execute its growth plans in the global rare disease arena.

Key Stats

• Today's Range: $40.00 to $40.00
• 50-Day Range: $40.00 to $40.00
• 52-Week Range: $15.25 to $43.00
• Volume: N/A
• Average Volume: 10,339 shs
• Market Capitalization: $1.19 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

CALT Stock Analysis - Frequently Asked Questions

How have CALT shares performed this year?

Calliditas Therapeutics AB (publ)'s stock was trading at $40.0001 at the beginning of the year. Since then, CALT stock has increased by 0.0% and is now trading at $40.0001.

How were Calliditas Therapeutics AB (publ)'s earnings last quarter?

Calliditas Therapeutics AB (publ) (NASDAQ:CALT) released its quarterly earnings results on Tuesday, August, 13th. The company reported ($0.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.25) by $0.09. The company earned $52.36 million during the quarter, compared to analysts' expectations of $42.89 million. Calliditas Therapeutics AB (publ) had a negative net margin of 30.18% and a negative trailing twelve-month return on equity of 212.04%.
Read the conference call transcript.

When did Calliditas Therapeutics AB (publ) IPO?

Calliditas Therapeutics AB (publ) (CALT) raised $179 million in an initial public offering on Friday, June 5th 2020. The company issued 9,200,000 shares at a price of $19.50 per share. Citigroup, Jefferies and Stifel served as the underwriters for the IPO and Carnegie was co-manager.

How do I buy shares of Calliditas Therapeutics AB (publ)?

Shares of CALT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Calliditas Therapeutics AB (publ) own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Calliditas Therapeutics AB (publ) investors own include Advanced Micro Devices (AMD), Celsius (CELH), NIO (NIO), NVIDIA (NVDA), Reata Pharmaceuticals (RETA), Target (TGT) and Athenex (ATNX).

Company Calendar

• Last Earnings: 8/13/2024
• Today: 9/04/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:CALT
• CIK: 1795579
• Web: www.calliditas.se
• Phone: 46-0-841-130-05
• Fax: N/A
• Employees: 180
• Year Founded: 2004

Profitability

• EPS (Trailing Twelve Months): ($1.85)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$43.96 million
• Net Margins: -30.18%
• Pretax Margin: -29.40%
• Return on Equity: -212.04%
• Return on Assets: -27.96%

Debt

• Debt-to-Equity Ratio: 9.44
• Current Ratio: 2.69
• Quick Ratio: 2.59

Sales & Book Value

• Annual Sales: $1.60 billion
• Price / Sales: 0.74
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.06 per share
• Price / Book: 37.74

Miscellaneous

• Outstanding Shares: 29,790,000
• Free Float: 29,135,000
• Market Cap: $1.19 billion
• Optionable: Optionable
• Beta: 1.77